Crinetics Pharma ((CRNX)) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Crinetics Pharmaceuticals is conducting an extension study titled ‘An Open-label, Long-term Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894.’ The study aims to assess the long-term safety, tolerability, and efficacy of atumelnant (CRN04894) in treating Congenital Adrenal Hyperplasia, a significant condition affecting adrenal gland function.
The intervention being tested is atumelnant, an orally active nonpeptide melanocortin 2 receptor antagonist. This drug is designed to counteract the effects of adrenocorticotropic hormone, potentially offering a new treatment avenue for patients with this condition.
This Phase 2 study follows an interventional, single-group model with no masking, focusing primarily on treatment. Participants will receive open-label treatment for up to two years, with doses not exceeding those explored in previous studies.
The study began on November 27, 2024, with primary completion expected in the near future. The latest update was submitted on September 19, 2025, indicating ongoing recruitment and progress.
The continuation of this study could influence Crinetics Pharma’s stock performance positively, as successful outcomes might enhance investor confidence and position the company favorably against competitors in the endocrine disorder treatment market.
The study is currently ongoing, with further details available on the ClinicalTrials portal.